Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

Lymphoma, T-Cell, Peripheral Clinical Trial

Official title:

Phase I/II Study of Ixazomib and Romidepsin in Relapsed/ Refractory Peripheral T-cell Lymphoma (PTCL)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03547700
• Other study ID #: BTCRC-HEM15-028
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: September 26, 2018
• Est. completion date: July 2021

Study information

• Verified date: January 2021
• Source: Big Ten Cancer Research Consortium
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Single arm phase I/II study of ixazomib and romidepsin in relapsed/refractory PTCL. Each cycle is 28 days. Patients will continue to receive therapy until progressive disease, unacceptable toxicity, or if any other withdrawal criteria are met. The phase I study includes three dose levels. The phase II study will include treatment with ixazomib and romidepsin at the MTD established in the Phase I study.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 11
• Est. completion date: July 2021
• Est. primary completion date: March 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.

• Age = 18 years at the time of consent.

• ECOG Performance Status of 0-2 within 14 days prior to registration.

• Histological confirmation of peripheral T-cell lymphoma (PTCL) and biopsy confirmation of disease relapse (after initial or any subsequent salvage therapy).

• Documented disease progression after receiving at least one prior therapeutic regimen.

• Prior cancer treatment must be completed at least 28 days prior to registration and the subject must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to = Grade 1 or baseline. Systemic steroids at a dose less than the equivalent of 10 mg/day of prednisone and inhaled, nasal, and topical steroids are permitted. Intermittent dexamethasone for the treatment of nausea/emesis is also permitted.

• Absolute Neutrophil Count (ANC) = 1000/mm3

• Platelets (Plt) = 75,000/mm3

• Calculated creatinine clearance = 30 cc/min using the Cockcroft-Gault formula

• Bilirubin = 1.5 × upper limit of normal (ULN), (exception of Gilbert disease)

• Aspartate aminotransferase (AST) = 3 × ULN, if known hepatic involvement then = 5 × ULN

• Alanine aminotransferase (ALT) = 3 × ULN, if known hepatic involvement then = 5 × ULN

• Females of childbearing potential must have a negative serum pregnancy test within 14 days prior to registration. NOTE: Females are considered of child bearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are naturally postmenopausal for at least 12 consecutive months.

• Males must be willing to abstain from donating sperm or semen from the time of informed consent until 90 days after treatment discontinuation.

• The subject must have the ability to understand and comply with study procedures for the entire length of the study, as determined by the treating physician or protocol designee.

Exclusion Criteria:

• A history of, or a concurrent, clinically significant illness, medical condition or laboratory abnormality that, in the investigator's opinion, could affect the conduct of the study.

• Active infection requiring systemic therapy

• Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).

• Known additional malignancy that is active and/or progressive requiring treatment; exceptions include basal cell or squamous cell skin cancer, in situ cervical or bladder cancer, or other cancer for which the subject has been disease-free for at least two years.

• Active central nervous system (CNS) lymphoma

• Major surgery or radiation therapy within 28 days of study registration

• Uncontrolled infectious disease, including active herpes simplex or herpes zoster

• Known positive test for Hepatitis B surface antigen, Hepatitis C, or HIV. NOTE:

testing is not required.

• Known GI disease or GI procedure that could interfere with the oral absorption or tolerance of oral medications including difficulty swallowing, as determined by the treating physician.

• Evidence of uncontrolled cardiovascular conditions, including uncontrolled hypertension, cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months.

• Q-T interval, based on Bazett-corrected interval > 0.45 sec

• Treatment with any investigational drug within 28 days prior to registration.

• Peripheral neuropathy = grade 2

• Prior treatment with bortezomib, ixazomib, or romidepsin.

• Systemic treatment, within 14 days, with strong inhibitors of CYP1A2 (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of CYP3A (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of St. John's wort.

• Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.

• Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.

• Prior autologous hematopoietic stem cell transplant within 90 days of study registration.

• Prior allogeneic hematopoietic stem cell transplant.

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, T-Cell
• Lymphoma, T-Cell, Peripheral

Intervention

Drug:
• Romidepsin
Romidepsin is a histone deacetylase (HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from acetylated lysine residues in histones, resulting in the modulation of gene expression.
• Ixazomib
Ixazomib is a reversible proteasome inhibitor. Ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome.

Locations

Country	Name	City	State
United States	University of Michigan Comprehensive Cancer Center	Ann Arbor	Michigan
United States	University of Illinois Cancer Center	Chicago	Illinois
United States	Karmanos Cancer Center (Wayne State University)	Detroit	Michigan
United States	Indiana University Melvin and Bren Simon Cancer Center	Indianapolis	Indiana
United States	University of Iowa Hospitals and Clinics	Iowa City	Iowa
United States	University of Minnesota	Minneapolis	Minnesota
United States	Rutgers Cancer Institute of New Jersey	New Brunswick	New Jersey

Sponsors (3)

Lead Sponsor	Collaborator
Ryan Wilcox	Takeda, University of Michigan Rogel Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase I: Assess adverse events	To evaluate the safety of ixazomib when given in combination with romidepsin to establish the maximum tolerated dose (MTD) of this combination, per CTCAE v4.	12 months
Primary	Phase II: Complete Response Rate (CR)	To determine the complete response (CR) rate of this combination in relapsed/refractory PTCL. CR, defined as complete metabolic response recorded from first day of treatment until disease progression or initiation of new antineoplastic therapy, as per the Lugano response criteria.	36 months
Secondary	Phase II: Overall Response Rate (ORR)	OR, defined as complete or partial metabolic response recorded from first day of treatment until disease progression/recurrence or initiation of new antineoplastic therapy, as per the Lugano response criteria.	36 months
Secondary	Phase II: Duration of Response (DOR)	DOR, defined as time that measurement criteria are met for complete or partial metabolic response (whichever status is recorded first) until disease progression/recurrence or initiation of new antineoplastic therapy, as per the Lugano response criteria.	36 months
Secondary	Phase II: Time To Next Treatment (TTNT)	TTNT defined as the date of initiation of treatment until death or the date of initiation of the next treatment.	36 months
Secondary	Phase II: Overall Survival (OS)	OS, defined as time from first day of treatment to time of death.	36 months